Rhythm Pharmaceuticals logo
Rhythm Pharmaceuticals RYTM
$ 113.05 -0.45%

Quarterly report 2025-Q3
added 11-04-2025

report update icon

Rhythm Pharmaceuticals Income Statement 2011-2025 | RYTM

Annual Income Statement Rhythm Pharmaceuticals

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

3.34 B 2.5 B 1.35 B 495 M 1.31 B 645 M 821 M 424 M - - - - - -

Shares

61 M 57.7 M 52.1 M 49.6 M 44.1 M 36.4 M 31 M 13.3 M - - - - - -

Historical Prices

54.7 43.4 25.9 9.98 29.7 23 26.9 29.1 - - - - - -

Net Income

-261 M -185 M -181 M -69.6 M -134 M -141 M -74.1 M -33.7 M -25.9 M -11.1 M - -21.4 M -18.1 M -

Revenue

130 M 77.4 M 23.6 M 3.15 M - - - - - - - - - -

Cost of Revenue

13.4 M 9.3 M 2.13 M 599 K - - - - 2.73 M 3.16 M - - - -

Operating Income

-266 M -184 M -179 M -170 M -137 M -146 M -78.4 M -32.4 M -25.9 M -10.6 M - - - -

Interest Expense

2.24 M 190 K -790 K 100 M - - - - - - - - - -

EBITDA

-265 M -183 M -178 M -169 M -136 M -145 M -78 M -32.2 M -25.8 M -10.1 M - -21.4 M -18.1 M -

Operating Expenses

- - - - - 146 M 78.4 M 32.4 M - - - - - -

General and Administrative Expenses

144 M 118 M 92 M 68.5 M 46.1 M 36.6 M 28.1 M 9.52 M 6.31 M 3.42 M - 3.43 M 2.46 M -

All numbers in USD currency

Quarterly Income Statement Rhythm Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

66.3 M 63.7 M 63.1 M 62.4 M 61.2 M 61 M 60.1 M 59.4 M 57.9 M 56.9 M 56.7 M 56.6 M 51.4 M 50.4 M 50.3 M 50.3 M 50.2 M 50.2 M 47.6 M 44.2 M 44.1 M 44.1 M 44 M 44 M 34.5 M 34.5 M 34.4 M 34.4 M 34.3 M 28 M 27.3 M 27.3 M 6.4 M 10.2 M 10.2 M 10.2 M 10.2 M - - - - - - - - - - - - - - - - - - - - - -

Net Income

-52.9 M -46.6 M -49.5 M - -43.6 M -32.3 M -141 M - -44.2 M -46.7 M -52.2 M - -40.9 M -45 M -52.8 M - -35.1 M -35.4 M 43.8 M - -33.8 M -31.1 M -34.2 M -33 M -36 M -42.8 M -29 M -25.5 M -17.7 M -14.4 M -16.5 M -10.5 M -10 M -6.8 M -6.36 M -8.37 M -25.9 M -5.73 M -5.38 M - - - - - - - - - - - - - - - - - - - -

Revenue

51.3 M 48.5 M 32.7 M - 33.3 M 29.1 M 26 M - 22.5 M 19.2 M 11.5 M - 4.28 M 9.07 M 1.5 M - 1.03 M 274 K 35 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

5.5 M 5.54 M 3.65 M - 3.83 M 2.95 M 2.81 M - 2.41 M 2.24 M 1.42 M - 497 K 378 K 230 K - 222 K 137 K 4 K - - - - - - - - - - - - - - - - - 2.73 M - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-52.7 M -45.3 M -47 M - -43.9 M -40.5 M -140 M - -44 M -46.6 M -52.5 M - -39.3 M -45.1 M -52.7 M - -44.2 M -40.4 M -34.4 M - -34.3 M -31.9 M -35.3 M - -37.1 M -44.1 M -30.5 M - -19.2 M -15 M -17 M - -8.29 M -6.75 M -6.39 M - -6.4 M - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

274 K 1.58 M -644 K - 1.09 M 302 K 524 K - -159 K -17 K 3.06 M - 2.14 M 46 K -233 K - 100 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - - - - - -52.3 M - -39.1 M -45.1 M -52.6 M - -44.1 M -40.3 M -34.2 M - -33.8 M -31.6 M -35.1 M - -36.5 M -43.7 M -30.3 M - -19 M -14.9 M -16.9 M - -8.12 M -6.65 M -6.34 M - -6.31 M - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - 34.3 M 31.9 M 35.3 M 34.2 M 37.1 M 44.1 M 30.5 M 27.2 M 19.2 M 15 M 17 M 11 M 8.29 M 6.75 M 6.39 M 8.38 M 6.4 M 5.74 M 5.39 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

52.4 M 45.9 M 39.1 M - 35.4 M 36.4 M 34.4 M - 30.5 M 30 M 24.6 M - 21.9 M 22.3 M 21.4 M - 17.5 M 15.5 M 14.5 M - 11.3 M 8.92 M 12.8 M - 10.5 M 8.84 M 7.76 M - 8.54 M 6.44 M 4.72 M - 2.32 M 1.36 M 1.52 M - 982 K - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Rhythm Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.93 4.78 % $ 818 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.2 -1.69 % $ 247 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.07 -5.75 % $ 295 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 213.33 -3.22 % $ 5 B danmarkDanmark
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.13 -4.96 % $ 7.53 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioVie BioVie
BIVI
$ 1.42 -1.85 % $ 2.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 93.93 -0.93 % $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.45 4.67 % $ 1.28 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.6 0.37 % $ 141 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.26 -6.98 % $ 566 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.98 -7.91 % $ 854 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 548.58 -2.78 % $ 41.6 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.37 2.83 % $ 14.9 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 91.59 1.95 % $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.09 -1.53 % $ 1.74 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.97 -0.44 % $ 1.45 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.33 -1.78 % $ 733 M usaUSA
Biogen Biogen
BIIB
$ 175.2 0.63 % $ 25.5 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.07 -5.5 % $ 108 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 87.67 -0.36 % $ 9.05 B usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 1.43 -36.18 % $ 18.8 K usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 3.28 -9.39 % $ 40.1 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.29 2.84 % $ 2.88 B usaUSA